Abstract
Thymosin fraction 5 contains a family of polypeptides with varying biological activities. Current efforts in the thymosin research program are involved in further chemical characterization of thymosin peptides and evaluation of clinical immunotherapeutic protocols. Recent clinical studies with thymosin fraction 5 have shown therapeutic potentials for treatment of patients with primary immunodeficiency diseases and cancer.
Cite
CITATION STYLE
Marshall, G. D., Thurman, G. B., Low, T. L., & Goldstein, A. L. (1980). Thymosin: basic properties and clinical application in the treatment of immunodeficiency diseases and cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer, 75, 100–105. https://doi.org/10.1007/978-3-642-81491-4_16
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
